不可切除胰腺腺癌患者接受内镜或经皮介入治疗的生存分析
基于监测、流行病学和最终结果-医疗保险数据库的回顾性队列研究,纳入14,808例不可切除胰腺癌患者,比较ERCP与经皮经肝胆道引流(PTBD)及是否行胆道引流的生存差异;ERCP与较PTBD降低死亡风险相关,两者较无胆道引流均与生存获益相关。
要点
- 在不可切除胰腺癌患者中,ERCP与较PTBD降低死亡风险相关(aHR 0.67,95%CI 0.60-0.75)。
- ERCP或PTBD较无胆道引流均与生存获益相关(aHR分别为0.51和0.53)。
- ERCP较PTBD平均住院时间更短(7.0±5.7天 vs 9.6±6.6天,P<.001)且住院费用更低。
核心结论
- 在胰腺癌患者中,ERCP与较PTBD降低死亡风险相关,凸显ERCP在处理胰腺癌所致胆道梗阻中的关键作用。
研究设计与样本
- 回顾性队列研究,使用监测、流行病学和最终结果-医疗保险数据库,纳入有胰头肿块和/或胆道梗阻证据的已知胰腺癌患者14,808例。
主要发现
- 14,808例不可切除胰腺癌患者中,8,898例(60.0%)接受胆道引流,5,910例(39.9%)未接受胆道干预。
- 胆道干预中ERCP占多数(8,271例,93.0%),623例(7.0%)接受PTBD。
- 多变量分析中,ERCP与较PTBD降低死亡风险相关(校正风险比[aHR] 0.67;95%置信区间[CI] 0.60-0.75)。
- ERCP或PTBD与无胆道干预相比,两者均与生存获益相关(aHR分别为0.51[95%CI 0.49-0.54]和0.53[95%CI 0.48-0.59])。
- 与PTBD相比,ERCP患者平均住院时间更短(分别为7.0±5.7天 vs 9.6±6.6天;P<.001),住院费用更低(分别为54,899.25美元 vs 75,246.00美元,P<.001),但住院率或30天再入院无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Most patients with pancreatic cancer are diagnosed at a late stage and are not candidates for surgical resection. Many have jaundice requiring biliary drainage, which can be accomplished using ERCP or percutaneous transhepatic biliary drainage (PTBD). To date, no studies have evaluated the impact of ERCP or PTBD on survival among patients with unresectable pancreatic cancer. The aims of our study were to compare overall survival between patients with unresectable pancreatic cancer receiving ERCP with those receiving PTBD, to compare overall survival between patients who received a biliary intervention (ERCP or PTBD) versus those who received no biliary intervention, and to compare secondary outcomes, such as length of hospital stay and costs, between ERCP and PTBD. METHODS: We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results-Medicare database. Patients with known pancreatic cancer were included if they had a pancreatic head mass and/or evidence of biliary obstruction. We used a time-varying Cox proportional hazards model to estimate overall survival of patients receiving ERCP versus PTBD and overall survival among patients who received a biliary intervention versus no biliary drainage. Secondary outcomes included length of hospital stay, costs, and admissions within 30 days. RESULTS: Of 14,808 patients with unresectable pancreatic cancer, 8898 patients (60.0%) underwent biliary drainage and 5910 patients (39.9%) received no biliary intervention. ERCP accounted for most biliary interventions (8271, 93.0%), whereas 623 patients (7.0%) underwent PTBD. In multivariable analysis, ERCP was associated with reduced mortality compared with PTBD (adjusted hazard ratio [aHR], .67; 95% confidence interval [CI], .60-.75). When ERCP or PTBD was compared with no biliary intervention, both procedures were associated with a survival benefit (aHR, .51 [95% CI, .49-.54] and .53 [95% CI, .48-.59], respectively). Compared with patients receiving PTBD, those who underwent ERCP had shorter mean length of hospital stay (7.0 ± 5.7 days vs 9.6 ± 6.6 days, respectively; P < .001) and lower hospital charges ($54,899.25 vs $75,246.00, P < .001) but no significant difference in hospitalization or 30-day readmissions. CONCLUSIONS: ERCP is associated with reduced mortality compared with PTBD in pancreatic cancer patients, highlighting the critical role of ERCP in the management of biliary obstruction from pancreatic cancer.
引用
- Tavakkoli A, Elmunzer BJ, Waljee AK, et al. Survival analysis among unresectable pancreatic adenocarcinoma patients undergoing endoscopic or percutaneous interventions. Gastrointest Endosc. 2020. PMID: 32531402. doi:10.1016/j.gie.2020.05.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。